Evolus
EOLS
7.59
-0.15
-1.94%
Evolus
US · EOLS
#3736 by market cap
Listed 2018
7.59
-0.15
-1.94%
Live - 5344 symbols - heartbeat 410s ago
· 2026-10-08 10:11
Pre-market
7.69
-0.65%
After-hours
7.74
0.00%
Overnight
7.74
0.00%
- Market cap
- 501.32M
- P/E (TTM)i
- -14.32
- P/Bi
- -16.22
- EPSi
- -0.80
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on EOLS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -1.76, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +11.61% YoY
Margins
- Gross margin
- 66.33%
- Operating margin
- -12.65%
- Net margin
- -17.38%
Key ratios & quality
- Enterprise valuei
- 596.12M
- Altman Z-Scorei
- -1.76
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 34.93M | 56.54M | 99.67M | 148.62M | 202.09M | 266.27M | 297.18M |
| Gross profit | 0 | 26.91M | 38.24M | 56.14M | 89.77M | 137.57M | 182.30M | 197.11M |
| Selling & admin expenses | 29.15M | 113.59M | 98.19M | 112.07M | 141.84M | 164.94M | 198.03M | 220.79M |
| Research & development | 6.49M | 3.97M | 1.72M | 2.06M | 6.74M | 15.43M | 9.17M | 9.58M |
| Operating profit | -35.64M | -94.79M | -68.70M | -63.62M | -59.58M | -44.98M | -27.24M | -37.60M |
| Pretax profit | -46.80M | -105.06M | -162.94M | -46.77M | -74.32M | -61.51M | -49.76M | -50.96M |
| Tax | 65.00K | -15.03M | 77.00K | 42.00K | 95.00K | 176.00K | 664.00K | 677.00K |
| Net profit | -46.87M | -90.03M | -163.01M | -46.81M | -74.41M | -61.69M | -50.42M | -51.64M |
| Basic EPS | -2 | -3 | -5 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.92 | -3.19 | -4.83 | -0.94 | -1.33 | -1.08 | -0.81 | -0.80 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 68.52M | 69.39M | 68.97M | 90.30M | 73.14M | 84.08M |
| Gross profit | 46.66M | 45.32M | 45.84M | 59.29M | 48.90M | 57.18M |
| Selling & admin expenses | 56.64M | 56.68M | 52.82M | 54.66M | 51.98M | 57.05M |
| Research & development | 2.21M | 1.84M | 2.05M | 3.48M | 2.24M | 1.89M |
| Operating profit | -13.02M | -14.12M | -10.16M | -291.00K | -6.86M | -3.29M |
| Pretax profit | -18.82M | -17.09M | -15.57M | 515.00K | -10.42M | -8.21M |
| Tax | 72.00K | 53.00K | 167.00K | 385.00K | 256.00K | -154.00K |
| Net profit | -18.89M | -17.14M | -15.74M | 130.00K | -10.67M | -8.05M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.30 | -0.27 | -0.24 | 0.00 | -0.16 | -0.12 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 94.34M | 152.20M | 127.61M | 178.80M | 100.80M | 112.42M | 151.34M | 142.92M |
| Cash & ST investments | 93.16M | 129.80M | 107.56M | 146.26M | 53.92M | 62.84M | 86.95M | 53.83M |
| Inventory | 0 | 6.41M | 3.35M | 1.76M | 18.85M | 11.00M | 12.16M | 26.96M |
| Total assets | 171.84M | 240.44M | 209.07M | 257.48M | 177.98M | 189.00M | 232.57M | 225.87M |
| Total current liabilities | 5.28M | 24.44M | 180.25M | 57.66M | 46.51M | 48.29M | 62.96M | 75.31M |
| Short-term debt | -- | 1.20M | 94.66M | 1.27M | 1.32M | 1.38M | 1.72M | 2.53M |
| Long-term debt | 16.90M | 91.45M | 40.51M | 71.22M | 71.88M | 120.36M | 121.51M | 146.10M |
| Total liabilities | 87,460,000.00 | 160,985,000.00 | 282,026,000.00 | 175,607,000.00 | 159,484,000.00 | 209,687,000.00 | 227,047,000.00 | 248,974,000.00 |
| Total equity | 84.38M | 79.46M | -72.96M | 81.88M | 18.50M | -20.69M | 5.52M | -23.11M |
| Retained earnings | -123.03M | -213.06M | -376.07M | -422.88M | -497.29M | -558.98M | -609.40M | -661.04M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 131.72M | 144.97M | 134.89M | 142.92M | 138.92M | 167.54M |
| Cash & ST investments | 67.89M | 61.74M | 43.52M | 53.83M | 49.79M | 45.17M |
| Inventory | 10.03M | 26.46M | 32.87M | 26.96M | 24.80M | 40.90M |
| Total assets | 213.36M | 228.80M | 219.00M | 225.87M | 220.65M | 248.02M |
| Total current liabilities | 56.23M | 63.75M | 66.71M | 75.31M | 68.02M | 98.73M |
| Short-term debt | 1.97M | 2.39M | 2.48M | 2.53M | 2.55M | 2.57M |
| Long-term debt | 121.81M | 145.48M | 145.78M | 146.10M | 156.41M | 156.74M |
| Total liabilities | 219,965,000.00 | 247,455,000.00 | 247,757,000.00 | 248,974,000.00 | 249,427,000.00 | 278,927,000.00 |
| Total equity | -6.60M | -18.65M | -28.76M | -23.11M | -28.78M | -30.90M |
| Retained earnings | -628.29M | -645.43M | -661.17M | -661.04M | -671.71M | -679.77M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -25.67M | -93.38M | -57.87M | -33.39M | -84.91M | -34.01M | -18.00M | -42.27M |
| Depreciation & amortization | 9.00K | 5.01M | 7.68M | 6.31M | 4.50M | 5.87M | 6.02M | 8.74M |
| Free cash flow | -25.68M | -97.95M | -61.01M | -34.36M | -87.85M | -35.64M | -22.82M | -50.72M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 124.01M | 73.32M | 0 | 103.34M | 0 | 0 | 51.21M | 0 |
| Ending cash balance | 93.16M | 109.89M | 102.56M | 146.26M | 53.92M | 62.84M | 86.95M | 53.83M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -15.63M | -24.79M | -14.67M | 12.83M | -9.95M | -3.59M |
| Depreciation & amortization | 1.83M | 2.05M | 2.28M | 2.59M | 2.69M | 2.69M |
| Free cash flow | -17.49M | -27.06M | -16.83M | 10.66M | -11.64M | -4.09M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 67.89M | 61.74M | 43.52M | 53.83M | 49.79M | 45.17M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -1,060.22 | -109.90 | -5,016.56 | -1,049.79 | -148.27 | -- | -- | -- |
| ROA %i | -28.92 | -43.68 | -72.53 | -20.07 | -34.18 | -33.62 | -23.92 | -22.53 |
| ROIC %i | -217.52 | -60.90 | -129.11 | -41.26 | -53.95 | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -1,476.95 | -- | -- | -- |
| EBIT margin %i | -- | -278.05 | -269.60 | -45.52 | -43.88 | -23.59 | -11.65 | -10.52 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 17.88 | 6.23 | 0.71 | 3.10 | 2.17 | 2.33 | 2.40 | 1.90 |
| Quick ratioi | 17.66 | 5.75 | 0.65 | 2.79 | 1.64 | 1.93 | 2.14 | 1.44 |
| Debt / assetsi | 9.84 | 40.15 | 66.16 | 29.03 | 41.81 | 66.96 | 55.89 | 68.62 |
| LT debt / equityi | 20.03 | 120.00 | -- | 89.74 | 395.17 | -- | 2,322.73 | -- |
| Interest coveragei | -53.23 | -12.21 | -14.51 | -32.50 | -7.17 | -3.45 | -1.66 | -1.59 |
| Revenue CAGR (3Y) %i | 0.00 | -- | -- | -- | 62.05 | 52.89 | 38.76 | 25.98 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -949.46 | -18,729.61 | -- | -- | -- | -- |
| ROA %i | -25.57 | -26.80 | -26.11 | -22.53 | -20.01 | -14.40 |
| ROIC %i | -33.02 | -33.81 | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -13.46 | -14.51 | -13.13 | -10.52 | -7.72 | -5.52 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.34 | 2.27 | 2.02 | 1.90 | 2.04 | 1.70 |
| Quick ratioi | 2.05 | 1.72 | 1.41 | 1.44 | 1.50 | 1.09 |
| Debt / assetsi | 61.02 | 67.70 | 70.73 | 68.62 | 74.74 | 66.45 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -2.01 | -1.92 | -1.85 | -1.59 | -1.21 | -1.08 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Jeuveau ® is the largest reported line at 88.55% of revenue, across 3 reported segments.
- The next-largest line, Evolysse ®, is a distant second at 10.58% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Jeuveau ®88.55%
Evolysse ®10.58%
Service revenue0.87%
Quote time 2026-10-08 10:11:01 · For reference only, not investment advice and not tailored to your situation.